<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03743896</url>
  </required_header>
  <id_info>
    <org_study_id>ASC/CPROJ/14/15/16</org_study_id>
    <secondary_id>CTC1600169</secondary_id>
    <nct_id>NCT03743896</nct_id>
  </id_info>
  <brief_title>Transdermal Delivery of Glucosamine to the Synovial Fluid of Male and Female With Knee Osteoarthritis</brief_title>
  <official_title>An Open Label, Single Dose, Bioavailability Study of Topical Transdermal Glucosamine Cream on the Synovial Fluid Tapped From Osteoarthritic Adult, Male and Female Human Subjects Already Undergoing Arthrocentesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lynk Biotechnologies Pte Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>T&amp;T Family Health Clinic and Surgery, Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Temasek Polytechnic School of Applied Science, Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lynk Biotechnologies Pte Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glucosamine is commonly used as a treatment for Osteoarthritis (OA). While oral
      administration remains the most commonly used route, topical administration could offer
      numerous advantages such as targeted delivery to affected joints and overcoming the negative
      effects of the passage of the drug through the digestive system. The objective of this study
      is to assess the bioavailability of glucosamine in the synovial fluid of osteoarthritic
      joints, following the topical application of a commercially available transdermal glucosamine
      cream. Joint fluid samples will be collected from 2 groups of participants with knee OA: the
      Control group will not be subjected to any treatment while the Test group will apply 2g of
      transdermal glucosamine cream 1 to 3 hours before the joint fluid collection. Glucosamine
      concentration will be determined and the results obtained from both groups will be compared.
      This trial will potentially provide data to support that glucosamine can cross the skin and
      be delivered to the affected joint fluid when formulated in a transdermal cream base.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 18, 2016</start_date>
  <completion_date type="Actual">March 10, 2017</completion_date>
  <primary_completion_date type="Actual">March 10, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects who agreed to participate in the study could decide to be part of the Control group (no intervention) or the Test group (single dose, topical application of Transdermal Glucosamine Cream)</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>There is no possibility of subjective bias or placebo effect since the primary outcome is the drug concentration in the synovial fluid. Hence no blinding or randomization needed.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of glucosamine in synovial fluid</measure>
    <time_frame>1 to 3 hours post-intervention</time_frame>
    <description>For the Test group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of glucosamine in synovial fluid</measure>
    <time_frame>At baseline</time_frame>
    <description>For the Control group</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose (2g), topical application of Transdermal Glucosamine Cream (containing 10% w/w of glucosamine sulfate)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transdermal Glucosamine Cream</intervention_name>
    <arm_group_label>Test group</arm_group_label>
    <other_name>TGCÂ® Plus Capsaicin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and non-pregnant female human subjects

          -  21 to 80 years old

          -  Subjects who need to undergo arthrocentesis (prescribed during prior medical
             assessment)

          -  Willingness to follow the protocol requirements

        Exclusion Criteria:

          -  Known allergy to shellfish

          -  Known history of hypersensitivity to Glucosamine or related drugs.

          -  Known history of hypersensitivity to Capsaicin (Capsicum extract)

          -  Known history of skin sensitivity

          -  Subjects who have taken any kind of glucosamine during the last 24 hours

          -  Subjects who have taken any kind of treatment for joint pain during the last 24 hours

          -  Subjects having scars/cut/dermatological abnormality at application site

          -  Pregnant or nursing women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Choon Meng Ting, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>T&amp;T Family Health Clinic and Surgery, Singapore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>T&amp;T Family Heath Clinic and Surgery</name>
      <address>
        <city>Singapore</city>
        <zip>208533</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 13, 2018</study_first_submitted>
  <study_first_submitted_qc>November 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2018</study_first_posted>
  <last_update_submitted>November 13, 2018</last_update_submitted>
  <last_update_submitted_qc>November 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transdermal Delivery</keyword>
  <keyword>Glucosamine</keyword>
  <keyword>Synovial Fluid</keyword>
  <keyword>Osteoarthritis</keyword>
  <keyword>Knee</keyword>
  <keyword>Human</keyword>
  <keyword>Arthrocentesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capsaicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 21, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/96/NCT03743896/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

